anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown to rapidly restore platelet numbers and reduce the risk of severe end-organ damage when added to plasma exchanges (PEXs) and immunosuppression (IST). Here, we report the outcomes in 3 children with aTTP who were treated with caplacizumab in combination with PEXs and IST. In all 3 patients, platelet count increased to >15,000/mm 3 in 24 h and normalized on day 4, whereas normalization of ADAMTS13 activity >50% and elimination of the inhibitor was achieved after 18 to 89 days. Epistaxis was observed in 2 patients and was the only side effect related to caplacizumab. Caplacizumab is a promising agent for first-line treatment of children with aTTP.
Physiotherapy students during their studying in the physiotherapy Bachelor degree program will be examined. Students will be divided into 2 groups according to their year of studying (if they already studied "women health course or not implying 4th year students compared with 1-3 year level students). Each participant will be asked to contract the pelvic floor muscles.

The assessment of pelvic floor contraction will be measured by measuring bladder displacement via abdominal ultrasound. A curved linear array transducer will be placed in the transverse plane immediately suprapubically over the lower abdomen angled at 15-30 degrees from the vertical. Upward movement of the bladder during contraction will be marked as correct contraction. An on screen caliper and measurement tool will be used to measure bladder amount of bladder displacement.
The present invention relates to nutrition gruel for treating constipation, which belongs to the field of health food. The nutrition gruel is characterized in that traditional Chinese drug materials: 10 parts of perilla seeds, 15 parts of flaxseeds, 15 parts of apricot kernels, 12 parts of tuckahoe, 15 parts of astragalus roots, 10 parts of solomonseal rhizome, 10 parts of Chinese angelica roots, 50 parts of non-glutinous rice, and 6 parts of radix et rhizoma rhei are adopted, by weight, to prepare the nutrition gruel. The present invention has the processing method that all traditional Chinese drug materials (except for the non-glutinous rice) are boiled in water for 20 minutes, and juice which is obtained after the traditional Chinese drug materials are filtered is cooked into gruel together with the non-glutinous rice. The nutrition gruel has the functions of coordinating the intestine and stomach and loosening the bowel to relieve constipation, and does not produce dependence. The healing rate reaches 98%, and the effective rate is as high as 100%. Therefore, the nutrition gruel is suitable for older adults, parturients and patients with difficult defaecation duo to weak health, intestine dryness and dry feces.
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma. Recurrence rate is still high. The standard management is total thyroidectomy. regional lymph node metastasis is noted in recurrent cases. Some studies stated benefits of central neck dissection in orevention of recurrence and others said there is no benefits. so prophylactic central neck dissection (pCND) remain controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC).
Citrus huanglongbing (HLB) is a major challenge that impacts the flourishing of the citrus industry. Therefore, analyzing the genomic information of HLB-resistant or tolerant citrus resources is crucial for breeding HLB-resistant citrus varieties. The Carrizo citrange, a hybrid of Citrus sinensis and Poncirus trifoliata, plays a pivotal role in citrus cultivation. However, its genetic explorations are difficult due to the absence of a reference genome or full-length transcriptome. In order to enhance our understanding of the genetic information of citrange, we conducted a full-length transcriptomic sequencing of multiple tissues from the Carrizo citrange using the PacBio Sequel II platform. Moreover, we performed gene ontology (GO) annotation, gene functional annotation, simple sequence repeats (SSR) types analysis, as well as identification of lncRNAs, alternative splicing events, and analysis of pathogen defense-related genes. Results showed that a total of 43,452 isoforms were generated, with 43,307 of them being annotated. GO annotation indicated the involvement of these isoforms in various biological processes, cellular components, and molecular functions. The coding sequence length of the isoforms ranged from 1,000 to 4,000 base pairs (bp). Moreover, we have discovered 54 varieties of transcription factors and regulators, along with 16 classifications of genes associated with resistance. Among all types of SSRs, trimer type SSRs were the most abundant. 130 lncRNAs were predicted to be highly reliable in the isoforms of the Carrizo citrange, with alternative splicing events identified, and the most frequent being retained intron. The analysis of gene family expansion and contraction revealed a significant increase in pathogen defense-related genes within the Carrizo citrange. The results of this study will be of great value for future investigations into gene function in citrange and for expanding the genetic pool for breeding citrus varieties resistant or tolerant to HLB.
This is a Phase 3, randomized (study medication assigned to participants by chance), open-label (identity of study drug will be known to participant and study staff), controlled study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in part, which will be conducted before starting the randomized part (Part 2) of the study and Part 2 is a randomized and open-label study. Part 1 and Part 2 of the study will be conducted in 3 phases: a Pretreatment (Screening) Phase (Up to 14 days before administration of study drug), a Treatment Phase, and a Posttreatment Phase. The Treatment Phase will extend from enrollment (in Part 1) or randomization (in Part 2) until 1 of the following: 1) completion of 3 cycles of therapy, 2) transplantation, if clinically indicated, or 3) progressive disease (PD), whichever comes first. The Posttreatment Phase will continue until death, loss to follow up, consent withdrawal, or study end, whichever occurs first. The end of study is defined as when approximately 60 event-free survival (EFS) events have occurred in Part 2 (death, disease progression, or lack of complete response \[CR\] or partial response \[PR\] after 3 cycles of treatment based on blinded independent event review), or the sponsor terminates the study, whichever comes first. Participants in Part 1 will be 1 to less than (\<) 18 years old. Participants in Part 2 will be 1 to 30 years old. Participants will be primarily evaluated for pharmacokinetics in part 1 and efficacy (EFS) of ibrutinib in combination with RICE or RVICI background therapy compared to RICE or RVICI background therapy alone in part 2. Participants' safety will be monitored throughout the study.
Purpose: Breastfeeding is associated with numerous short- and long-term neonatal and maternal health benefits. Specifically, in BRCA1/2 female carriers, breastfeeding has been shown to reduce the considerably increased risks of breast and ovarian cancer. Nevertheless, there is paucity of data referring to the recommended postpartum surveillance of BRCA1/2 carriers. The purpose of this study was to evaluate the recommendations of health professionals regarding breastfeeding in BRCA carriers. Methods: This cross-sectional survey was conducted using an anonymous questionnaire distributed through the "Good BRCA Genes-a support and information group for BRCA carriers" association. The questionnaire included Likert scale and open-ended questions, aimed to evaluate the performance of health professionals at various aspects of the recommended follow-up. Results: Of the 388 participants, 233 (60.0%) expressed dissatisfaction with explanations provided by health professionals regarding pregnancy and breastfeeding. Women reporting dissatisfaction with explanations were younger (36.8 ± 7.0 years) compared to those satisfied with the explanations (38.8 ± 7.6 years, p = 0.0081). No significant differences were noted between women satisfied and those dissatisfied with the explanations in terms of age of genetic diagnosis, origin, religion, geographic location, and the rates of personal or familial cancer history. Of the 175 responses to an open question "please describe the reasons for unsatisfactory explanation," 76.6% stated they received no explanation on the subject, whereas 5.4% described minimal explanation or conflicting recommendations. Surprisingly, 4.7% recalled being advised to avoid, stop, or limit breastfeeding. Discussion: The results of this survey emphasize the lack of knowledge of health professionals on the issue of breastfeeding in BRCA carriers. As genetic variants in these genes involve significant proportion of the population (up to 2.5% in Ashkenazi Jewish population), raising the awareness of health care personnel to the benefits of breastfeeding in these women seems prudent.
The invention discloses an application of Fingolimod (Code FTY720) in preparing a medicine for inhibiting liver cancer intrahepatic metastasis. The application belongs to the field of medicine novel purpose. According to the invention, human liver cancer cell nude mouse in-situ transplanted tumor models are established; when the tumors are formed, the mice are randomly divided into a control group and a Fingolimod treatment group; the mice are killed after two weeks, and tumor sizes and intrahepatic metastasis conditions are recorded. As a result, in the liver cancer in-situ transplanted tumor models, Fingolimod can inhibit liver tumor increasing and reducing intrahepatic metastasis. Therefore, Fingolimod can be used for preparing medicines used for inhibiting liver cancer intrahepatic metastasis. Fingolimod has good development and application prospect. The invention discloses for a first time the applcaiiton of Fingolimod in preparing the medicine for inhibiting liver cancer intrahepatic metastasis.
The present invention relates to a method for the detection and diagnosis of AIDS (acquired immune deficiency syndrome) ARC (AIDS Related Complex) and pre-AIDS conditions in body fluids by the use of a chemically synthesized peptide. The peptide has an amino acid sequence corresponding to a segment of the envelope protein, p41, of HTLV-III and has been found to be highly immunoreactive with antibodies in sera of patients with AIDS, ARC and pre-AIDS conditions. More specifically, the present invention is directed to the use of a chemically synthesized peptide containing therein a segment of about twenty-one (21) amino acids, or their analogues, in a prescribed sequence for the detection of antibodies to the HTLV-III virus in human body fluids of AIDS, ARC or pre-AIDS patients. The detection method includes an enzyme-linked immunosorbent assay (ELISA), an immunoradiometric assay (IRMA), and other forms of immuno assay procedures such as enzyme immuno blotting assay on nitrocellulose paper and hemagglutination assay using the peptide as the antigen. The preferred detection method is ELISA. The present invention also relates to a vaccine and a method for generating antibodies to HTLV-III in healthy mammals, including humans by the use of the chemically synthesized 21mer peptide or its analogues.
BACKGROUND: Delayed response to clinical deterioration of hospital inpatients is common. Deployment of an electronic automated advisory vital signs monitoring and notification system to signal clinical deterioration is associated with significant improvements in clinical outcomes but there is no evidence on the cost-effectiveness compared with routine monitoring, in the National Health Service (NHS) in the United Kingdom (UK).
METHODS: A decision analytic model was developed to estimate the cost-effectiveness of an electronic automated advisory notification system versus standard care, in adults admitted to a district general hospital. Analyses considered: (1) the cost-effectiveness of the technology based on secondary analysis of patient level data of 3787 inpatients in a before-and-after study; and (2) the cost-utility (cost per quality-adjusted life-year (QALY)) over a lifetime horizon, extrapolated using published data. Analysis was conducted from the perspective of the NHS. Uncertainty in the model was assessed using a range of sensitivity analyses.
RESULTS: The study population had a mean age of 68 years, 48% male, with a median inpatient stay of 6 days. Expected life expectancy at discharge was assumed to be 17.74 years. (1) Cost-effectiveness analysis: The automated notification system was more effective (-0.027 reduction in mean events per patient) and provided a cost saving of -£12.17 (-182.07 to 154.80) per patient admission. (2) Cost-utility analysis: Over a lifetime horizon the automated notification system was dominant, demonstrating a positive incremental QALY gain (0.0287 QALYs, equivalent to ~10 days of perfect health) and a cost saving of £55.35. At a threshold of £20,000 per QALY, the probability of automated monitoring being cost-effective in the NHS was 81%. Increased use of cableless sensors may reduce cost-savings, however, the intervention remains cost-effective at 100% usage (ICER: £3,107/QALY). Stratified cost-effectiveness analysis by age, National Early Warning Score (NEWS) on admission, and primary diagnosis indicated the automated notification system was cost-effective for most strategies and that use representative of the patient population studied was the most cost-saving strategy.
CONCLUSION: Automated notification system for adult patients admitted to general wards appears to be a cost-effective use in the NHS; adopting this technology could be good use of scarce resources with significance for patient safety.
Alcohol and marijuana (AM) are the most commonly used substances among adolescents in the U.S. The consequences of AM use are significantly higher relative to use of either substance alone. This study builds on effective interventions that have demonstrated reductions in alcohol and/or marijuana use and reduced consequences one year later, and proposes to adapt one of those interventions, CHAT, to the web (web-CHAT). The investigators will evaluate the efficacy of web-CHAT among 15.5-17-year-old adolescents (n=150) recruited when teen participants are attending behind-the-wheel training. The study has the potential to promote public welfare by improving adolescent health outcomes and reducing risky driving behaviors that can have substantial monetary and social costs, as well as by providing unique insight into what mediates reduced risky driving attitudes behaviors among those in the intervention. The study is innovative because it is for both youth who are at risk for substance use as well as those who are not, and it is delivered during a teachable moment when adolescents receive driver's education. Finally, this study can provide unique insights about the efficacy of web-CHAT to reduce marijuana initiation, use, and risky driving attitudes in the context of a changing marijuana policy climate. A 3-year study is proposed to test the feasibility of research procedures in a driver education setting and pilot the efficacy of web-CHAT. The investigators will test whether web-CHAT reduces alcohol and/or marijuana initiation or use compared to teens in UC, at three and six-month follow-up.
Patients present a wide range of clinical severities in response severe acute respiratory syndrome coronavirus 2 infection, but the underlying molecular and cellular reasons why clinical outcomes vary so greatly within the population remains unknown. Here, we report that negative clinical outcomes in severely ill patients were associated with divergent RNA transcriptome profiles in peripheral immune cells compared with mild cases during the first weeks after disease onset. Protein-protein interaction analysis indicated that early-responding cytotoxic natural killer cells were associated with an effective clearance of the virus and a less severe outcome. This innate immune response was associated with the activation of select cytokine-cytokine receptor pathways and robust Th1/Th2 cell differentiation profiles. In contrast, severely ill patients exhibited a dysregulation between innate and adaptive responses affiliated with divergent Th1/Th2 profiles and negative outcomes. This knowledge forms the basis of clinical triage that may be used to preemptively detect high-risk patients before life-threatening outcomes ensue.
Rationale: This is a Phase 2 study of folate-hapten conjugate therapy in combination with low-doses of the cytokines Interleukin-2 (IL-2) and Interferon-alpha (INF-alpha). Folate-hapten conjugate treatment consists of subcutaneous vaccinations with EC90, a compound designed to elicit an immune response (antibodies) to a dye called fluorescein (FITC), in combination with GPI-0100 adjuvant (a drug intended to improve antibody production). Vaccination is followed by treatment with EC17, a drug made by linking folate (a vitamin) with FITC. Experimental evidence has shown that the folate receptor is over-expressed in many human cancers, including renal cell carcinoma. It is expected that EC17 will attach to cancer cells through the folate receptor and that antibodies to FITC will recognize the cancer cell and mark it for destruction by the body's immune system. Two drugs, IL-2 and IFN-alpha, will be administered at low doses in combination with EC17 in order to boost the immune response. During the screening period, all potential patients will undergo imaging with 99mTc-EC20 (a technetium-based, folate- linked radiopharmaceutical \[EC20\]) for the purpose of identifying patients whose tumors express the folate receptor; the target of folate-hapten conjugate therapy. Prior to receiving EC90/GPI-0100 and EC17 therapy, patients must exhibit at least one tumor lesion that displays adequate uptake of 99mTc-EC20 during the imaging procedure.
In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
BACKGROUND: Prader-Willi syndrome (PWS) is a rare, neurodevelopmental disorder caused by the lack of expression of paternally imprinted genes on chromosome 15q11-13. PWS features a complex behavioral phenotype, including hyperphagia, anxiety, compulsivity, rigidity, repetitive speech, temper outbursts, aggressivity, and skin-picking. Questionnaires exist for measuring hyperphagia, but not for the aggregation of other problems that are distinctive to PWS. A PWS-specific tool is needed for phenotypic research, and to help evaluate treatment efficacy in future clinical trials aimed at attenuating PWS's hyperphagia and related problems. In this 4-phase study, we leveraged our expertise in PWS with feedback from families and specialists to validate the PWS Profile, a novel, informant-based measure of behavioral and emotional problems in this syndrome.
RESULTS: The authors developed a bank of 73 items that tapped both common and less frequent but clinically significant problems in PWS (Phase 1). An iterative feedback process with families and stakeholders was used to ensure content and construct validity (Phase 2). After adding, omitting, or revising items, in Phase 3, we pilot tested the measure in 112 participants. Results were reviewed by an international team of PWS specialists and revised again (Phase 3). The final, 57-item Profile was then administered to 761 participants (Phase 4). Principal component factor analyses (n = 873) revealed eight conceptually meaningful factors, accounting for 60.52% of test variance, and were readily interpretated as: Rigidity, Insistence; Aggressive Behaviors; Repetitive Questioning, Speech; Compulsive Behaviors; Depression, Anxiety; Hoarding; Negative Distorted Thinking; and Magical Distorted Thinking. Factors were internally consistent and showed good test-retest reliability and convergent validity with existent measures of behavioral problems. Profile factors were not related to IQ, BMI, or parental SES. Three Profile factors differed across PWS genetic subtypes. Age and gender differences were found in only one Profile factor, Hoarding.
CONCLUSIONS: The PWS Profile is a valid, psychometrically-sound questionnaire that already has shown responsivity to treatment in a previous clinical trial. The Profile can extend the reach of future clinical trials by evaluating the impact of novel agents not only on hyperphagia, but also on the emotional and behavioral problems that characterize PWS.
<P>PROBLEM TO BE SOLVED: To provide an excellent enteric preparation which does not need water, when orally taken, can also easily be taken by a swallowing-difficult patient, and has improved compliance.  <P>SOLUTION: This enteric preparation is characterized by comprising a medicine, pectin and water. The preparation is not dissolved under an acidic condition having a pH 1.2 to 3.5 which is the pH of gastric juice, is quickly dissolved at a pH 6 to 8 in large intestine, and can sufficiently correspond to demands as the enteric preparation. The preparation can be obtained by compounding water in the preparation. The preparation can be prepared in a dosage form such as a liquid preparation, a jelly preparation, an ointment-like preparation or a cream preparation, does not need water when taken, can also easily be taken by a swallowing-difficult patient, and has improved compliance.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
We will undertake a cluster randomised trial of the efficacy of medical drone use by randomization of health facilities and their associated landing sites in Kalangala District. There are 64 landing sites and 18 health facilities. The unit of radomisation will be the landing site, so that all persons at one landing site will receive the drone delivery or boat delivery, facility pick-up. This will avoid contamination of drone delivery by sharing of ART between people getting drone and boat or other modes of deliveries. Bias in this situation will be managed by stratifying the landing sites by distance from drone operations base (a proxy of delivery cost), and number of decentralised service delivery (DSD) groups. Bias in gender and age will be managed at selection of members in DSD groups. We will also undertake a cost effectiveness analysis, carbon analysis and process evaluation. A qualitative study will assess acceptability and additional use cases
Non-adaptive multi-domain computerized training included tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
In this invention, an ensemble learning model (REGX) is used to diagnose and prognose COVID-19. The ensemble learning model uses two layers of multiple classifiers to improve model performance. The first level of diversity classifier includes additional trees, random forests, gradient boosting and extreme gradient boosting models, after which the output of the first level is sent to the second level SVM classifier. Also, during data preprocessing, the knnimpers algorithm is used herein to process null values, use ifest to filter outliers, and then use a few over-sampling techniques (SMOTE) to equalize the data distribution. Finally, feature importance is reported by features_importances (scikit-Learn) and SHapley Additive exPlanations (SHAP) to meet the need for model interpretability in a medical environment. Finally, the important biomarkers revealed in the black box model that might be ignored by healthcare practitioners due to the proliferation of new coronavirus infected patients were revealed by the features_importants and SHAP post-hoc interpretability in sklearn.